Woodview Home, Inc. in Ardmore, OK

Woodview Home, Inc. is a medicare and medicaid certified nursing home in Ardmore, Oklahoma. It is located in Carter county at 1630 3rd Avenue Northeast, Ardmore, Oklahoma 73401. You can reach out to the office of Woodview Home, Inc. via phone at (580) 226-5454. This skilled nursing facility has 68 federally certified beds with average occupancy rate of 57.06%. Its legal business name is Woodview Home, Inc. and has the following ownership type - For Profit - Corporation.

Woodview Home, Inc. (Medicare CCN 375393) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2001 (23 years certified) and the last quality survey was conducted in January, 2020.

Name	Woodview Home, Inc.
Location	1630 3rd Avenue Northeast, Ardmore, Oklahoma
Certified By	Medicare and Medicaid
No. of Certified Beds	68
Occupancy Rate	57.06%
Medicare ID (CCN)	375393
Legal Business Name	Woodview Home, Inc.
Ownership Type	For Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Woodview Home, Inc. from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Woodview Home, Inc. are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Woodview Home, Inc. give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

UC San Diego researchers suggest transplanting good bacteria to treat patients with atopic dermatitis

Healthy human skin is alive with bacteria. In fact, there are more microorganisms living in and on the human body than there are human cells. Most can live on the human skin without harming the host, but in some people bacteria can negatively alter their health, maybe even become life-threatening.

Court's review of Medicaid expansion could affect other federal programs

A major issue in the Supreme Court battle over the new health care law is whether Congress can force states to make a huge expansion of Medicaid, to add millions of low-income people to the rolls. States say the federal law is unconstitutionally coercive because all their Medicaid money would be at risk if they flout the new requirement. The states argument has implications that go far beyond health care.

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

Read more Medical News

› Verified 2 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	0
Total Amount of Fines in Dollars	$0
Number of Payment Denials	0
Total Number of Penalties	0

The resident survey data of Woodview Home, Inc. is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	12.18	14.46
Percentage of long-stay residents who lose too much weight	8.33	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	55.81	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	0	1.79
Percentage of long-stay residents with a urinary tract infection	0	2.65
Percentage of long-stay residents who have depressive symptoms	0.66	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	10.71	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	99.4	93.87
Percentage of long-stay residents who received an antipsychotic medication	21.09	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	73.68	83.88